Recently, 23andMe announced a collaboration with Pfizer Inc, allowing researchers with the drug maker to leverage 23andMe’s unique platform to conduct genome-wide associations studies, surveys and clinical trial recruitment.
The news follows a collaboration began last summer between 23andMe and Pfizer to enroll 10,000 people in a study to explore the genetic factors associated with the onset, progression, severity and response to treatment for Inflammatory Bowel Disease.The collaboration with Pfizer — as well as work with academic researchers and other companies such as Genentech, Reset Therapeutics and others — is part of an effort by 23andMe to offer qualified and approved scientists outside of 23andMe a chance to leverage our unique research platform for discovery.
For more about 23andMe’s collaborations see their CEO’s interview on CNBC.
The preceding article is content provided by our sponsor 23andMe.com. The views and opinions expressed in the content above are not the views and opinions of IBD News Today or its parent company, BioNews Services, LLC.